Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Sheila A Doggrell. (2008) Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?. Expert Opinion on Pharmacotherapy 9:3, pages 405-420.
Read now
Read now
Jodi Sparkman, Jeffrey Stroup, Ryan Schupbach & Ryan Carnahan. (2007) Metabolic Effects of a Conversion from Rosiglitazone to Pioglitazone in Native American Patients with Type 2 Diabetes. Baylor University Medical Center Proceedings 20:4, pages 349-353.
Read now
Read now
Jerry R Colca & Rolf F Kletzien. (2006) What has prevented the expansion of insulin sensitisers?. Expert Opinion on Investigational Drugs 15:3, pages 205-210.
Read now
Read now
Charles G. Gegick & Michael D. Altheimer. (2004) Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors. Current Medical Research and Opinion 20:6, pages 919-930.
Read now
Read now
Anne L. Peters Harmel, David M. Kendall, John B. Buse, Patrick J. Boyle, Albert Marchetti & Helen Lau. (2004) Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Current Medical Research and Opinion 20:2, pages 215-223.
Read now
Read now
Hiroaki Seino, Hiyoshi Yamaguchi, Asako Misaki, Yoshiyuki Sakata, Masayuki Kitagawa, Toshirou Yamazaki, Hiroaki Kikuchi & Ryuzo Abe. (2003) Clinical effect of combination therapy of pioglitazone and an α-glucosidase inhibitor. Current Medical Research and Opinion 19:8, pages 675-682.
Read now
Read now
Pietro Gerber, Georg Lübben, Sabine Heusler & Ayako Dodo. (2003) Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Current Medical Research and Opinion 19:6, pages 532-539.
Read now
Read now
Articles from other publishers (31)
Manjunath Krishnappa, Kishor Patil, Krupi Parmar, Purav Trivedi, Nirali Mody, Chintan Shah, Khushboo Faldu, Sanjay Maroo, Piyush Desai, Kamlesh Fatania, Satyanarayan Murthy, R. Balamurugan, Manish Agarwal, K. P. Singh, G. S. Kalra, Vipul Khandelwal, Ashish Singwala, Hemant Thacker, Rahul Tulle, Harish Rao, Mukund Kumbla, Parminder Singh, Ashok Khatri, Sumit Agrawal, R. N. Sarkar, Dinesh Agarwal, Girish Bhatia, R. P. Agarwal, Surender Kumar, P. R. Vamsi Krishna, Ajay Kumar Ajmani, Amit Asalkar, Indraneel Basu, Sudip Chatterjee, Vinod Kumar Pavithran, Rupam Das, Aniruddha Dharmadhikari, Vikram Vardhan, M. Madusudhan Babu, Nilanjan Sengupta, Srirang Abkari, R. Harikrishna, Rashmi Chovatia & Deven Parmar. (2020) Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). Cardiovascular Diabetology 19:1.
Crossref
Crossref
Prachi Gupta, Manju Bala, Sanjeev Gupta, Anita Dua, Rajesh Dabur, Elisha Injeti & Ashwani Mittal. (2016) Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs—A mechanistic revisit to understand their mode of action. Pharmacological Research 113, pages 636-674.
Crossref
Crossref
Richard B. Aguilar. (2011) Evaluating Treatment Algorithms for the Management of Patients With Type 2 Diabetes Mellitus: A Perspective on the Definition of Treatment Success. Clinical Therapeutics 33:4, pages 408-424.
Crossref
Crossref
Minghan Wang. 2011. Metabolic Syndrome. Metabolic Syndrome
253
278
.
Jessica Triay, Rajeev Raghavan, Andrew Day, Parag SinghalGiles Osborne. (2011) Changes in lipid parameters in patients with type 2 diabetes following a switch from rosiglitazone to pioglitazone in primary and secondary care: a prospective, descriptive study. The British Journal of Diabetes & Vascular Disease 11:1, pages 31-37.
Crossref
Crossref
Giuseppe Derosa. (2010) Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus. Drugs 70:15, pages 1945-1961.
Crossref
Crossref
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
Harold BaysJennifer McElhattanBrian S Bryzinski. (2016) A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus. Diabetes and Vascular Disease Research 4:3, pages 181-193.
Crossref
Crossref
Kazim Sahin, Muhittin Onderci, Mehmet Tuzcu, Bilal Ustundag, Gurkan Cikim, İbrahim H. Ozercan, Vidyasagar Sriramoju, Vijaya Juturu & James R. Komorowski. (2007) Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat. Metabolism 56:9, pages 1233-1240.
Crossref
Crossref
G. Derosa, A. D’Angelo, P. D. Ragonesi, L. Ciccarelli, M. N. Piccinni, F. Pricolo, S. A. T. Salvadeo, L. Montagna, A. Gravina, I. Ferrari, S. Paniga & A. F. G. Cicero. (2007) Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Internal Medicine Journal 37:2, pages 79-86.
Crossref
Crossref
W Fernando Trigoso. (2006) Comparative Study of Thiazolidinediones in Clinical Use. The Endocrinologist 16:5, pages 271-278.
Crossref
Crossref
Paulos Berhanu, Mark S Kipnes, Mehmood A Khan, Alfonso T Perez, Stuart F Kupfer, Robert G Spanheimer, Seleshi Demissie & Penny R Fleck. (2016) Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diabetes and Vascular Disease Research 3:1, pages 39-44.
Crossref
Crossref
Giuseppe Derosa, Arrigo F.G. Cicero, Angela D'Angelo, Antonio Gaddi, Leonardina Ciccarelli, Mario N. Piccinni, Sibilla A.T. Salvadeo, Fabio Pricolo, Ilaria Ferrari, Alessia Gravina & Pietro D. Ragonesi. (2006) Effects of 1 Year of Treatment with Pioglitazone or Rosiglitazone Added to Glimepiride on Lipoprotein (a) and Homocysteine Concentrations in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Multicenter, Randomized, Double-Blind, Controlled Clinical Trial. Clinical Therapeutics 28:5, pages 679-688.
Crossref
Crossref
Wan-Sub ShimMi-Young DoSoo-Kyung KimHae-Jin KimKyu-Yeon HurEun-Seok KangYu-Mie RheeChul-Woo AhnSung-Kil LimKyung-Rae KimHyun-Chul LeeBong-Soo Cha. (2006) The long term effects of rosiglitazone on serum lipid concentration and body weight. The Journal of Korean Diabetes Association 30:1, pages 17.
Crossref
Crossref
Á. Rodríguez Bernardino, S. Cebrián Blanco & S. Durán García. (2005) Pioglitazona. Revisión de sus efectos metabólicos y sistémicos. Revista Clínica Española 205:12, pages 610-620.
Crossref
Crossref
Ronald B. Goldberg, David M. Kendall, Mark A. Deeg, John B. Buse, Anthony J. Zagar, Jane A. Pinaire, Meng H. Tan, Mehmood A. Khan, Alfonso T. Perez & Scott J. Jacober. (2005) A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia. Diabetes Care 28:7, pages 1547-1554.
Crossref
Crossref
R. Mukhtar & J. P. D. Reckless. (2005) Dyslipidaemia in Type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone. Diabetic Medicine 22:s3, pages 6-10.
Crossref
Crossref
A. P. James, G. F. Watts & J. C. L. Mamo. (2005) The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects. Diabetes, Obesity and Metabolism 7:4, pages 381-389.
Crossref
Crossref
Kazunori Nagashima, Carlos Lopez, Daniel Donovan, Colleen Ngai, Nelson Fontanez, André Bensadoun, Jamila Fruchart-Najib, Steve Holleran, Jeffrey S. Cohn, Rajasekhar Ramakrishnan & Henry N. Ginsberg. (2005) Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. Journal of Clinical Investigation 115:5, pages 1323-1332.
Crossref
Crossref
J. William Lester & A.W. Fernandes. (2005) Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. International Journal of Clinical Practice 59:2, pages 134-142.
Crossref
Crossref
. (2005) Pioglitazone: a promising therapy for psoriasis. British Journal of Dermatology 152:1, pages 189-191.
Crossref
Crossref
Achikam Grinberg & Kyung W Park. (2005) Nuclear Peroxisome Proliferator-Activated Receptors and Thiazolidinediones. International Anesthesiology Clinics 43:2, pages 1-21.
Crossref
Crossref
H. Kim, M. Haluzik, O. Gavrilova, S. Yakar, J. Portas, H. Sun, U. B. Pajvani, P. E. Scherer & D. LeRoith. (2004) Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia 47:12, pages 2215-2225.
Crossref
Crossref
Jean-Frédéric Blicklé. (2004) Place des thiazolidinediones dans le traitement du diabète de type 2. La Presse Médicale 33:15, pages 1034-1040.
Crossref
Crossref
P. M. Srivastava, P. Calafiore, R. J. MacIsaac, D. L. Hare, G. Jerums & L. M. Burrell. (2004) Thiazolidinediones and congestive heart failure-exacerbation or new onset of left ventricular dysfunction?. Diabetic Medicine 21:8, pages 945-950.
Crossref
Crossref
Giuseppe Derosa, Arrigo F.G Cicero, Antonio Gaddi, Pietro D Ragonesi, Elena Fogari, Gianandrea Bertone, Leonardina Ciccarelli & Mario N Piccinni. (2004) Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clinical Therapeutics 26:5, pages 744-754.
Crossref
Crossref
Jerry R. Colca, William G. McDonald, Daniel J. Waldon, Joseph W. Leone, June M. Lull, Carol A. Bannow, Eric T. Lund & W. Rodney Mathews. (2004) Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe. American Journal of Physiology-Endocrinology and Metabolism 286:2, pages E252-E260.
Crossref
Crossref
Brad R Henke. 2004.
1
53
.
Jeroen P.H. van WijkEelco J.P. de KoningEdwin P. MartensTon J. Rabelink. (2003) Thiazolidinediones and Blood Lipids in Type 2 Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology 23:10, pages 1744-1749.
Crossref
Crossref
P. Zimmet & C. R. Thomas. (2003) Genotype, obesity and cardiovascular disease - has technical and social advancement outstripped evolution?. Journal of Internal Medicine 254:2, pages 114-125.
Crossref
Crossref